CY1114880T1 - Αγωνιστες mglu2 - Google Patents

Αγωνιστες mglu2

Info

Publication number
CY1114880T1
CY1114880T1 CY20131101012T CY131101012T CY1114880T1 CY 1114880 T1 CY1114880 T1 CY 1114880T1 CY 20131101012 T CY20131101012 T CY 20131101012T CY 131101012 T CY131101012 T CY 131101012T CY 1114880 T1 CY1114880 T1 CY 1114880T1
Authority
CY
Cyprus
Prior art keywords
mglu2 agonists
mglu2
agonists
fighters
schizophrenia
Prior art date
Application number
CY20131101012T
Other languages
Greek (el)
English (en)
Inventor
James Allen Monn
Lourdes Prieto
Martinez Lorena Taboada
Salgado Carlos Montero
Bruce William Shaw
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114880(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1114880T1 publication Critical patent/CY1114880T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20131101012T 2009-12-21 2013-11-14 Αγωνιστες mglu2 CY1114880T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
EP10798419.7A EP2516406B1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (1)

Publication Number Publication Date
CY1114880T1 true CY1114880T1 (el) 2016-12-14

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101012T CY1114880T1 (el) 2009-12-21 2013-11-14 Αγωνιστες mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (cg-RX-API-DMAC7.html)
EP (1) EP2516406B1 (cg-RX-API-DMAC7.html)
JP (1) JP5779190B2 (cg-RX-API-DMAC7.html)
KR (1) KR101395356B1 (cg-RX-API-DMAC7.html)
CN (1) CN102695701B (cg-RX-API-DMAC7.html)
AR (1) AR079343A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010340039B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017188B1 (cg-RX-API-DMAC7.html)
CA (1) CA2784667C (cg-RX-API-DMAC7.html)
CR (1) CR20120322A (cg-RX-API-DMAC7.html)
CY (1) CY1114880T1 (cg-RX-API-DMAC7.html)
DK (1) DK2516406T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000173A (cg-RX-API-DMAC7.html)
EA (1) EA020229B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011989A (cg-RX-API-DMAC7.html)
ES (1) ES2435651T3 (cg-RX-API-DMAC7.html)
HN (1) HN2012001160A (cg-RX-API-DMAC7.html)
HR (1) HRP20131052T1 (cg-RX-API-DMAC7.html)
IL (1) IL220011A (cg-RX-API-DMAC7.html)
JO (1) JO2978B1 (cg-RX-API-DMAC7.html)
MA (1) MA33824B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012007332A (cg-RX-API-DMAC7.html)
MY (1) MY160618A (cg-RX-API-DMAC7.html)
NZ (1) NZ600305A (cg-RX-API-DMAC7.html)
PE (1) PE20121688A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501253A1 (cg-RX-API-DMAC7.html)
PL (1) PL2516406T3 (cg-RX-API-DMAC7.html)
PT (1) PT2516406E (cg-RX-API-DMAC7.html)
RS (1) RS53063B (cg-RX-API-DMAC7.html)
SG (1) SG181836A1 (cg-RX-API-DMAC7.html)
SI (1) SI2516406T1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000281A1 (cg-RX-API-DMAC7.html)
TW (1) TWI477490B (cg-RX-API-DMAC7.html)
UA (1) UA107684C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011084437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2540728T1 (sl) 2010-02-17 2019-06-28 Takeda Pharmaceutical Company Limited Heterociklična spojina
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
ES2587204T3 (es) * 2011-06-17 2016-10-21 Eli Lilly And Company Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas del receptor mGlu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
CN109999033B (zh) * 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
CN1267407C (zh) * 2001-01-11 2006-08-02 伊莱利利公司 兴奋性氨基酸前体药物
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
JP4342437B2 (ja) * 2002-06-11 2009-10-14 イーライ リリー アンド カンパニー 興奮性アミノ酸のプロドラッグ
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists

Also Published As

Publication number Publication date
IL220011A (en) 2014-03-31
CA2784667A1 (en) 2011-07-14
CA2784667C (en) 2014-11-18
JP5779190B2 (ja) 2015-09-16
JP2013514974A (ja) 2013-05-02
CN102695701B (zh) 2014-10-01
HRP20131052T1 (hr) 2013-12-06
HN2012001160A (es) 2015-08-24
EA201290558A1 (ru) 2012-12-28
CN102695701A (zh) 2012-09-26
RS53063B (sr) 2014-04-30
BR112012017188A2 (pt) 2016-03-22
EA020229B1 (ru) 2014-09-30
NZ600305A (en) 2014-01-31
PL2516406T3 (pl) 2014-03-31
SG181836A1 (en) 2012-08-30
HK1171228A1 (en) 2013-03-22
TN2012000281A1 (en) 2013-12-12
MY160618A (en) 2017-03-15
TW201144290A (en) 2011-12-16
ECSP12011989A (es) 2012-07-31
EP2516406B1 (en) 2013-09-18
PH12012501253A1 (en) 2014-08-01
WO2011084437A1 (en) 2011-07-14
TWI477490B (zh) 2015-03-21
AU2010340039A1 (en) 2012-08-09
AR079343A1 (es) 2012-01-18
BR112012017188A8 (pt) 2016-10-04
IL220011A0 (en) 2012-07-31
PT2516406E (pt) 2013-10-10
CR20120322A (es) 2012-07-10
EP2516406A1 (en) 2012-10-31
PE20121688A1 (es) 2012-12-05
AU2010340039B2 (en) 2014-03-20
KR20120094056A (ko) 2012-08-23
US8318184B2 (en) 2012-11-27
DK2516406T3 (da) 2013-10-14
US20110152334A1 (en) 2011-06-23
MX2012007332A (es) 2012-07-20
UA107684C2 (xx) 2015-02-10
DOP2012000173A (es) 2012-11-30
KR101395356B1 (ko) 2014-05-14
BR112012017188B1 (pt) 2021-06-22
SI2516406T1 (sl) 2013-11-29
ES2435651T3 (es) 2013-12-20
MA33824B1 (fr) 2012-12-03
JO2978B1 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
CY1114880T1 (el) Αγωνιστες mglu2
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
CY1118250T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
EA201170227A1 (ru) Имидазолкарбоксамиды
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
CR11814A (es) Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
JO3715B1 (ar) منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني
UA106880C2 (uk) Нові гербіциди
ATE506385T1 (de) Nanoharnstoff-dispersionen
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
EA200701592A1 (ru) Композиты и способы их получения и использования
CR20110361A (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapeutica como activadores de hif
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
CO7160067A2 (es) Formulaciones de agonistas del receptor de somatostatina
RU2011118463A (ru) Ароматические блок-сополиэфиркетоны
CL2009000317A1 (es) Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.